Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle

被引：38

作者：

Patel, Harun M. ^{[1
]}

Pawara, Rahul ^{[1
]}

Ansari, Azim ^{[1
]}

Noolvi, Malleshappa ^{[2
]}

Surana, Sanjay ^{[1
]}

机构：

[1] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmaceut Chem, Shirpur 425405, Maharashtra, India

[2] Shree Dhanvantary Pharm Coll, Dept Pharmaceut Chem, Surat 3941110, Gujarat, India

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2017年 / 25卷 / 10期

关键词：

Quinazoline; Non Small Cell Lung Cancer; T790M EGFR; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; PAN-ERBB INHIBITOR; PHASE-II TRIAL; ACQUIRED-RESISTANCE; T790M MUTATION; IRREVERSIBLE INHIBITORS; ACCURATE DOCKING; GEFITINIB;

D O I：

10.1016/j.bmc.2017.03.039

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The epidermal growth factor receptor (EGFR) T790M mutant is found in about 50% of clinically acquired resistance to gefitinib among patients with non-small cell lung cancer (NSCLC). New derivatives of 4(3H)-quinazolinones were synthesized and evaluated for their inhibitory activity against NSCLC. The results of the study demonstrated that compound 79, 7-chloro-3-(5-(4-methoxypheny1)-1,3,4-thiadiazol-2-y1)-2-phenylquinazolin-4(3H)-one was found to be the most potent compounds of the series with IC50 value of 0.031 mu M against mutant T790M/L858R EGFR. Compounds 15, 51, 73, 75, 78, 79 and 96 were less potent against A549 (WT EGFR and k-Ras mutation) and HT-29 (non-special gene type) cells, showing a high safety index. The obtained results showed that compounds 15, 51, 73, 75, 78, 79 and 96 could be the promising template to overcome drug resistance mediated by the EGFR T790 Mutant. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：2713 / 2723

页数：11

共 50 条

[21] Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR
Lim, Sang Min
Jeong, Yujeong
Hong, Sungwoo
FUTURE MEDICINAL CHEMISTRY, 2016, 8 (08) : 853 - 878
[22] EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance
Robinson, Kyle W.
Sandler, Alan B.
CURRENT ONCOLOGY REPORTS, 2013, 15 (04) : 396 - 404
[23] Recent progress on third generation covalent EGFR inhibitors
Cheng, Hengmiao
Nair, Sajiv K.
Murray, Brion W.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (08) : 1861 - 1868
[24] Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors
Han, Chun
Huang, Zhangjian
Zheng, Chao
Wan, Ledong
Lai, Yisheng
Peng, Sixun
Ding, Ke
Ji, Hongbin
Zhang, Yihua
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 66 : 82 - 90
[25] The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors
Belani, Chandra P.
CANCER INVESTIGATION, 2010, 28 (04) : 413 - 423
[26] Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
Novak, Jennifer
Salgia, Ravi
West, Howard
Villalona-Calero, Miguel A.
Sampath, Sagus
Williams, Terence
Villaflor, Victoria
Massarelli, Erminia
Pathak, Ranjan
Koczywas, Marianna
Chau, Brittney
Amini, Arya
CANCERS, 2022, 14 (16)
[27] Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Taylor, T. E.
Furnari, F. B.
Cavenee, W. K.
CURRENT CANCER DRUG TARGETS, 2012, 12 (03) : 197 - 209
[28] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, Lihua
Fu, Liwu
ACTA PHARMACEUTICA SINICA B, 2015, 5 (05) : 390 - 401
[29] Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer
Tong, Christy W. S.
Wu, William K. K.
Loong, Herbert H. F.
Cho, William C. S.
To, Kenneth K. W.
CANCER LETTERS, 2017, 405 : 100 - 110
[30] Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Du, Xiaojing
Yang, Biwei
An, Quanlin
Assaraf, Yehuda G.
Cao, Xin
Xia, Jinglin
INNOVATION, 2021, 2 (02):

← 1 2 3 4 5 →